Tuberculosis Therapeutics: Market Research Report

April 2010 | 366 pages | ID: TDE8DD789FDEN
Global Industry Analysts, Inc

Abstracts

This report analyzes the Global market for Tuberculosis Therapeutics in US$ Million.

Annual estimates and forecasts are provided for the period 2006 through 2015.

The report profiles 37 companies including AstraZeneca, Bayer AG, Bristol-Myers Squibb Co., Eli Lilly and Company, GlaxoSmithKline Plc, Lupin Limited, Novartis AG, Ranbaxy Laboratories Limited, Rusan Pharma Ltd., Rx for Africa, Inc., Sanofi-Aventis SA, Summit Plc, Tibotec BVBA, Otsuka Pharmaceutical Co., Ltd., and Sequella, Inc.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.

Contents

I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1.INDUSTRY OVERVIEW

Tuberculosis: A Reality Check
Evolutionary Battle Against the TB Bug Drives the Future of the Market
TB Prevalence Statistics: A Current Review

Table 1. Worldwide Prevalence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart)

Table 2. Worldwide Incidence of TB Cases (in 000s) by Region for the Year (2007) (includes corresponding Graph/Chart)

Table 3. Worldwide TB Mortality (2009): Breakdown of Number of TB Deaths (in '000s) by Region (includes corresponding Graph/Chart)

Effectiveness of Current TB Management Strategies

Table 4. Currently Established TB First-Line Drugs, & Fixed-Dose Combination Drugs

Table 5. Currently Established TB Second-Line Drugs

Renewed Interest in TB Drugs Development
A Peek into the Current Drug Development Pipeline
TB Drugs in Pipeline as of the Year 2008
The Importance of Public-Private Partnerships (PPP)
The Promise of New Therapeutic Advancements
Nano Drug Delivery Offers a Ray of Hope
What’s The Need of the Hour?
Moving Research to Market…
Challenges in Drug Development
Antidotes
Recalibration of Drug Arsenal Against Resistant & HIV Co-Infected TB Cases
TB Research in Dire Need of Funding

Table 6. Global Tuberculosis R&D Investment for the years 2005 through 2008 (In US$ Million) (includes corresponding Graph/Chart)

Table 7. Worldwide TB Drugs Market (2007): Percentage Share Breakdown of Funding by Donor (includes corresponding Graph/Chart)

Table 8. Worldwide TB R&D Funding (2008): Percentage Share Breakdown of Allocated Funds by Area of Research (includes corresponding Graph/Chart)

Table 9. Global Tuberculosis R&D Investment: Breakdown of R&D Sponsors for the year 2008 (In US$ Million)

Table 10. Global Tuberculosis R&D Investment (2008): Percentage Share Breakdown of Funds by Donor Type (includes corresponding Graph/Chart)

Bottleneck in Logistics Need to be Ironed Out
Other Trends & Issues
The State of Research Funding Amidst the Recession…
Growth in Drug Resistant TB Cases Drive Second-Line Therapeutic Drugs Market
HIV Infections: A Major Catalyst in Global Increase of TB
Pharma Companies Called Upon to Focus on TB Drug Development
High Prevalence in Developing Countries offer a Strong Commercial Opportunity

Table 11. Prevalence of TB in High Burden Countries (2007): Percentage Share Breakdown of Prevalent Cases by Country (includes corresponding Graph/Chart)

Table 12. Burden of TB Worldwide (2007): Breakdown of Number of cases of TB Prevalence (‘000s) by Country (includes corresponding Graph/Chart)

Table 13. Burden of TB in High Burden Countries (2007): Breakdown of Number of Deaths (‘000s) by Country (includes corresponding Graph/Chart)

A Peek Into the Commitments Voiced by High Burden Countries
MDR-TB on the Rise in Dragon Land
What’s the Chinese Government Doing About It?
Indonesia: Pledges Support to TB Drug Research
South Africa Publicizes Its Commitment
Other Statistical Findings

Table 14. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Age Group for the year 2006 through 2008 (includes corresponding Graph/Chart)

Table 15. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Gender for the year 2006 through 2008 (includes corresponding Graph/Chart)

Table 16. Tuberculosis Prevalence in Japan: Breakdown of Notified Patients by Prefecture/Designated City for the year 2008 (includes corresponding Graph/Chart)

2.DISEASE & TREATMENT OVERVIEW

Tuberculosis (TB): A Prevalent, Yet Neglected Disease
Latent TB Infection
Active TB Infection
A Peek Into the Bacteria Causing the Disease…
Types of Tuberculosis
Pulmonary Tuberculosis
Extra Pulmonary Tuberculosis
Diagnosis of TB
Prevention of TB
The Cure
The DOTS Program: A Review
TB Drugs
First line Drugs
Isoniazid
Mode of Action & Dosage
Side Effects
Rifampin
Mode of Action
Side Effects
Pyrazinamide
Dosage
Mode of Action
Side Effects
Ethambutol
Mode of Action
Side Effects
Streptomycin
Second Line Drugs
Aminoglycosides
Mode of Action
Fluoroquinolones
Moxifloxacin (MXF)
Cycloserine
p-aminosalicylic acid (PAS or P)

3.RECENT INDUSTRY ACTIVITY

Across America Financial Services Acquires Apro Bio Pharmaceutical
Academia Sinica Inks MoU with Infectious Disease Research Institute
TB Alliance Enters into Collaboration with Tibotec
Rx for Africa Inks Letter of Intent with Rusan Pharma
Johnson & Johnson to Establish Drug Research Centre
Anacor Inks Agreements with Two Non-profit Organizations
Lupin Obtains USFDA Approval
Sequella Commence Phase IB Study for SQ109
Regional Model TB Center Establishes New Center
AstraZeneca to Commence Safety Studies for TB Drug Candidate
GADD and TIM Enters into Partnership
NWHD to Establish New Tuberculosis Facility
Cadila Pharmaceuticals Launches Risorine
Merck and Eli Lilly Collaborate for TB Treatment
Sanofi-aventis Enters into Collaboration with TB Alliance
Summit Corp Enters into Co development Agreement with Lilly PPP
NITD Collaborates with TB Alliance to Discover New Anti-TB Drugs
Ranbaxy Enters into Alliance with DBT for TB Drug Discovery and Research
Sanofi pasteur Inks License and Research Agreement with SSI

4.FOCUS ON SELECT GLOBAL PLAYERS

Profiles of generic drug companies & pharma majors, developing TB drugs in collaboration with not-for profit organizations & academic institutes
AstraZeneca (UK)
Bayer AG (Germany)
Bristol-Myers Squibb Co. (USA)
Eli Lilly and Company (USA)
GlaxoSmithKline Plc. (UK)
Lupin Limited (India)
Novartis AG (Switzerland)
Ranbaxy Laboratories Limited (India)
Rusan Pharma Ltd., (India)
Rx for Africa, Inc., (USA)
Sanofi-Aventis SA (France)
Summit Plc (UK)
Tibotec BVBA (Belgium)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Sequella, Inc., (USA)
Profiles of key non-profit organizations & academic institutes
Global Alliance for TB Drug Development (USA)
Research Project Pipeline of the Global Alliance for TB Drug Development As of the Year 2009
Institute of Microbiology, Chinese Academy of Sciences (China)

5.GLOBAL MARKET PERSPECTIVE

Table 17. World Recent Past, Current & Future Market Analysis for Tuberculosis (TB) Therapeutics Analyzed with Annual Sales in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)

III. COMPETITIVE LANDSCAPE

Total Companies Profiled: 37 (including Divisions/Subsidiaries - 41)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Africa